Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33 results about "Wnt inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
Described herein are methods of treating a disorder or disease in which aberrant Wnt signaling is implicated, with a variety of compounds, including Wnt inhibitor compounds. More particularly, it concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components.
Owner:SAMUMED LLC
Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
ActiveUS20050261181A1Improve biological activityPromote mineralizationBiocidePeptide/protein ingredientsOsteoblastWnt inhibitor
Compositions and methods for the treatment of bone diseases, bone fractures, bone injuries and other bone abnormalities involving the use of Dkk protein, a Wnt antagonist, a Wnt inhibitor, or any other related protein for the stimulation or enhancement of mineralization and for stimulating the renewal of cells. One Dkk protein, Dickkopf-2 (Dkk-2), acts to stimulate bone formation independently of Wnt proteins which may be inhibited and / or antagonized by Dkk-2. Dkk-2 displayed enhanced specific targeting ability and enhanced biological activity in stimulating or enhancing mineralization. Dkk-2 also played a role in the differentiation and self-renewal of hematopoietic stem cells and mesenchymal stem cells, particularly in osteoblastogenesis and osteoclastogenesis.
Owner:ENZO BIOCHEM
Use of WNT inhibitors to augment therapeutic index of chemotherapy
InactiveUS20080075714A1Increase dosePeptide/protein ingredientsAntibody mimetics/scaffoldsIntestinal structureWnt inhibitor
Methods and compositions are provided for the protection of normal cells from cytoreductive therapy that target proliferating cells, by administering an inhibitor of Wnt signaling pathways. Wnt signaling is critically important for homeostasis of the epithelial lining of the adult intestine and other proliferating normal adult tissues.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Production of Differentiated Enteroendocrine Cells and Insulin Producing Cells
ActiveUS20170349884A1Promote cell differentiationHigh expressionGastrointestinal cellsAntipyreticHistone methylationWnt inhibitor
A population of enteroendocrine cells (EEC) is obtained from a mammalian post-natal cell population, such as a population including post-natal stem cells, by treating the population with a plurality of small molecules that upregulate ChgA and promote differentiation of the cells to form the enteroendocrine cells. The upregulation of ChgA is such that the fraction of cells expressing CGA in the obtained cell population, as measured by a ChgA Immunostaining Assay, is at least about 1.5%. Small molecules that can be used to differentiate the post-natal cells into the enteroendocrine cells can include at least one of a Wnt activator, a Notch inhibitor, a Wnt inhibitor, a MEK / ERK inhibitor, a growth factor, a HDAC inhibitor, a Histone Methylation Inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator. Also, the insulin expression of a population of mammalian cells is increased by treating the population with a plurality of small molecules that increase the insulin expression.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +1
Use of WNT inhibitors to augment therapeutic index of chemotherapy
InactiveUS7803783B2Increase doseOrganic active ingredientsPeptide/protein ingredientsIntestinal structureWnt inhibitor
Methods and compositions are provided for the protection of normal cells from cytoreductive therapy that target proliferating cells, by administering an inhibitor of Wnt signaling pathways. Wnt signaling is critically important for homeostasis of the epithelial lining of the adult intestine and other proliferating normal adult tissues.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Inhibition of hair follicle growth by the wnt inhibitor dkk1
InactiveUS20120165270A1Prevent hair growthInhibit growthCosmetic preparationsOrganic active ingredientsWnt inhibitorDKK1
The invention provides methods of inhibiting hair growth in a post-natal subject by contacting a matured hair follicle cell with a DKK polypeptide. The inhibitory mechanism induced by a DKK polypeptide results in a reversible, transient inhibition of hair growth.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue
A method for generating chondrocytes and / or cartilage, optionally articular like non-hypertrophic chondrocyte cells and / or cartilage like tissue and / or hypertrophic chondrocyte like cells and / or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFR[alpha]+KDR- primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGF[beta] inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and / or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and / or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii. culturing the high cell density CD73+, CD105+ and / or PDGFR[beta]+ paraxial mesoderm population with a TGF[beta]3 agonist in serum free media to produce a high cell density Sox9+, collagen 2+ chondrocyte precursor population; and c. either i. culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor population with the TGFbeta3 agonist for an extended period of time to produce an articular like non-hypertrophic chondrocyte cells and / or cartilage like tissue; or ii. culturing the high cell density Sox9+ collagen2+ chondrocyte precursor population with a BMP4 agonist for an extended period of time to produce a hypertrophic chondrocyte like cells and / or cartilage like tissue.
Owner:UNIV HEALTH NETWORK
Modulation of cardiac stem-progenitor cell differentiation, assays and uses thereof
ActiveUS20150368618A1Profound impact growthProfound impact differentiationBiocideLibrary screeningStage specificGerm layer
The present invention relates to endogenous cardiac stem-progenitor cells (eCSCs). Provided herein are c-kitpos CD166pos eCSCs that are negative for the hematopoietic marker, CD45 and the mast cell marker, Tryptase. These single cell derived eCSCs can differentiate into a variety of specific cell types corresponding to the derivatives of the three germ layers. Also provided herein is a stage-specific TGF-P-Family / Wnt-Inhibitor cocktail for modulating in vitro myogenic specification and maturation of c-kitpos eCSCs. Also provided herein are methods of modulating eCSCs clonal expansion and differentiation. Also provided herein are screening assays for small organic molecules that modulate early cardiomyogenic progenitor cells. The invention further relates to the use of these modulated cells in prophylactic and therapeutic methods, including in pharmaceutical compositions of such cells, growth factors and / or small organic compounds. Finally, the invention relates to the use of such differentiated cells in transplantation and medical treatments.
Owner:NADAL GINARD BERNARDO
Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
ActiveUS8343922B2Improve biological activityPromote mineralizationBiocidePeptide/protein ingredientsOsteoblastWnt inhibitor
Compositions and methods for the treatment of bone diseases, bone fractures, bone injuries and other bone abnormalities involving the use of Dkk protein, a Wnt antagonist, a Wnt inhibitor, or any other related protein for the stimulation or enhancement of mineralization and for stimulating the renewal of cells. One Dkk protein, Dickkopf-2 (Dkk-2), acts to stimulate bone formation independently of Wnt proteins which may be inhibited and / or antagonized by Dkk-2. Dkk-2 displayed enhanced specific targeting ability and enhanced biological activity in stimulating or enhancing mineralization. Dkk-2 also played a role in the differentiation and self-renewal of hematopoietic stem cells and mesenchymal stem cells, particularly in osteoblastogenesis and osteoclastogenesis.
Owner:ENZO BIOCHEM
Application of Wnt inhibitor Wnt-C59 in preparation of medicine for treating dilated cardiomyopathy caused by SCN5A mutation
ActiveCN112472701AImproved heart function prognosisOrganic active ingredientsCardiovascular disorderGenes mutationWnt inhibitor
The invention relates to the technical field of biological medicines, in particular to application of a Wnt inhibitor Wnt-C59 in preparation of a medicine for treating dilated cardiomyopathy caused bySCN5A mutation. According to the invention, SCN5A genotype detection is used as an entry point for the first time, and a Wnt pathway specific inhibitor Wnt-C59 is used for inhibiting abnormal activation of a Wnt / beta-Catenin pathway caused by SCN5A gene mutation, so that the prognosis of the cardiac function of an expanded cardiomyopathy patient with SCN5A gene mutation is improved. According tothe experiment, the treatment effect of Wnt-C59 on the dilated heart disease is detected by constructing an aging and adriamycin induced dilated heart disease model, changing the cardiac function, activating related signal molecules and other indexes, and a theoretical basis is provided for application of Wnt-C59 to clinical treatment of dilated cardiomyopathy. The invention provides a new treatment method for the dilated cardiomyopathy caused by SCN5A mutation, brings dawn to the patients, and has a good application prospect.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV
Production of differentiated enteroendocrine cells and insulin producing cells
A population of enteroendocrine cells (EEC) is obtained from a mammalian post-natal cell population, such as a population including post-natal stem cells, by treating the population with a plurality of small molecules that upregulate ChgA and promote differentiation of the cells to form the enteroendocrine cells. The upregulation of ChgA is such that the fraction of cells expressing CGA in the obtained cell population, as measured by a ChgA Immunostaining Assay, is at least about 1.5%. Small molecules that can be used to differentiate the post-natal cells into the enteroendocrine cells can include at least one of a Wnt activator, a Notch inhibitor, a Wnt inhibitor, a MEK / ERK inhibitor, a growth factor, a HDAC inhibitor, a Histone Methylation Inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator. Also, the insulin expression of a population of mammalian cells is increased by treating the population with a plurality of small molecules that increase the insulin expression.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +1
Disubstituted and trisubstituted 1,2,3-triazoles as wnt inhibitors
The present disclosure provides compounds that may be useful for inhibiting Wnt pathway comprising compounds of the formula: (Ia) or (Ib) wherein the variables are as defined herein. In some aspects, the compounds may be used to inhibit the Wnt pathway and used to treat cancer, myocardial infarction, osteopetrosis, or used in the maturation of a precursor cell to a mature cell. Also provided herein in are pharmaceutical compositions of the compounds described herein.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Combination compositions for immunotherapy
InactiveUS20180153884A1Inhibit bindingOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsWnt inhibitorImmunotherapy
The present invention relates to therapeutic combinations comprising WNT inhibitors and methods for treating cancers using combination therapy.
Owner:CUREGENIX CORP
Application of wnt inhibitor in preparation of medicine for treating hematopoietic aplastic disorders
ActiveCN105854018BPromote regenerationPromote regeneration of knockout hematopoietic stem cellsTetrapeptide ingredientsGene therapyDiseaseMechanism of action
The invention discloses an application of a Wnt inhibitor ICG001 in the preparation of medicines for treating hematopoietic aregenerative diseases. The Wnt inhibitor ICG001 can inhibit a CBP mediated Wnt signal path in order to inhibit depletion of too high Wnt signal hematopoietic stem cells, induced by SIRT6 deletion. The invention discloses the application of the Wnt inhibitor ICG001 in the preparation of the medicines for treating hematopoietic aregenerative diseases, and an action mechanism of the ICG001 in promotion of regeneration of SIRT6 knockout hematopoietic stem cells.
Owner:佳康赛尔生物技术(云南)有限公司
Application of Wnt inhibitor in preparation of medicines for treating hematopoietic aregenerative diseases
ActiveCN105854018APromote regenerationPromote regeneration of knockout hematopoietic stem cellsTetrapeptide ingredientsGene therapyDiseaseWnt inhibitor
The invention discloses an application of a Wnt inhibitor ICG001 in the preparation of medicines for treating hematopoietic aregenerative diseases. The Wnt inhibitor ICG001 can inhibit a CBP mediated Wnt signal path in order to inhibit depletion of too high Wnt signal hematopoietic stem cells, induced by SIRT6 deletion. The invention discloses the application of the Wnt inhibitor ICG001 in the preparation of the medicines for treating hematopoietic aregenerative diseases, and an action mechanism of the ICG001 in promotion of regeneration of SIRT6 knockout hematopoietic stem cells.
Owner:佳康赛尔生物技术(云南)有限公司
Markers associated with wnt inhibitors
ActiveCN105190313AOrganic active ingredientsMicrobiological testing/measurementWnt inhibitorHead and neck
Owner:NOVARTIS AG
Combination therapy for treatment of cancer
The present invention provides methods comprising combination therapy for treating cancer. Wnt pathway inhibitors in combination with mitotic inhibitors administered in a staggered or sequential dosing manner for the treatment of cancer and other diseases.
Owner:ONCOMED PHARMA INC
Methods for improving proliferation and stemness of limbal stem cells
ActiveUS20170283773A1Increased proliferationInhibition of differentiationNervous system cellsCell culture supports/coatingΒ catenin signalingBeta-catenin
Provided are methods for improving the proliferation and sternness of limbal stem cells (LSCs) by adding a Wnt inhibitor to a medium for limbal explant cultures.When human limbal explants are cultured according to the methods, the Wnt / β-catenin signaling is inhibited, resulting in improvement of LSC proliferation, and improvement in the sternness of LSCs, and thus the LSCs may be obtained in high yield. These effects may lead to a higher success rate of transplantation of a limbal explant outgrowth sheet into a LSCD patient.
Owner:THE CATHOLIC UNIV OF KOREA IND ACADEMIC COOP FOUND
Markers associated with wnt inhibitors
ActiveUS20160024587A1Improve accuracyStrong specificityOrganic active ingredientsOrganic chemistryWnt inhibitorBiologic marker
The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Wnt inhibitor, methods of determining the sensitivity of a cell to an Wnt inhibitor by measuring biomarkers, methods of screening for candidate Wnt inhibitor, Wnt inhibitor for use in head and neck squamous cell carcinoma.
Owner:IRM +1
Application of wnt inhibitor wnt-c59 in preparation of medicine for scn5a mutation-induced dilated cardiomyopathy
ActiveCN112472701BImproved heart function prognosisOrganic active ingredientsCardiovascular disorderGenes mutationWnt inhibitor
The invention relates to the technical field of biomedicine, in particular to the application of Wnt inhibitor Wnt-C59 in the preparation of medicines for treating dilated cardiomyopathy caused by SCN5A mutation. The present invention proposes for the first time that SCN5A genotype detection is used as an entry point, and the Wnt pathway-specific inhibitor Wnt-C59 is used to inhibit the abnormal activation of the Wnt / β-Catenin pathway caused by the SCN5A gene mutation, so as to improve the dilated cardiomyopathy caused by the SCN5A gene mutation Patient cardiac function prognosis. The experiment established a model of heart dilation induced by aging combined with doxorubicin, and detected the therapeutic effect of Wnt‑C59 on heart dilation by changes in cardiac function and activation of related signaling molecules, so as to provide a theory for the clinical application of Wnt‑C59 in the treatment of dilated cardiomyopathy in accordance with. The invention provides a new treatment method for SCN5A mutation-induced dilated cardiomyopathy, brings dawn to this type of patients, and has a good application prospect.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV
Culture media for pluripotent stem cells
PendingUS20210363495A1Genetically modified cellsArtificially induced pluripotent cellsSrc inhibitorWnt inhibitor
A culture medium comprising a WNT inhibitor, a SRC inhibitor and a protein kinase C (PKC) inhibitor is disclosed. The medium is devoid of an amount of GSK3beta inhibitor that increases beta-catenin translocation to the nucleus of a pluripotent stem cell being cultured in the culture medium. Uses thereof are also disclosed.
Owner:YEDA RES & DEV CO LTD
Application of liquidambaric lactone in treatment of cancers
PendingCN112535689AHigh selectivityRich sourcesOrganic active ingredientsNervous disorderColon rectal cancerWnt inhibitor
Owner:SHANGHAI UNIV OF T C M
Method for promoting the differentiation of pluripotent stem cells into cardiomyocytes
ActiveCN108060125BPromote maturityOrderly rowsCulture processSkeletal/connective tissue cellsSerum freeWnt inhibitor
Owner:SUZHOU UNIV
Small molecule wnt inhibitor as treatment for dyslipidemia
Compositions and methods for treating cardiovascular diseases and dyslipidemias are provided. The compositions can inhibit Wnt signaling and can reduce inflammation. The levels of cholesterol can be reduced when the compositions are administered to a subject, such as a human.
Owner:YALE UNIV
Markers associated with Wnt inhibitors
ActiveUS10422007B2Increase valueImprove accuracyOrganic active ingredientsMicrobiological testing/measurementWnt inhibitorFhit gene
The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Wnt inhibitor, methods of determining the sensitivity of a cell to an Wnt inhibitor by measuring biomarkers, methods of screening for candidate Wnt inhibitor, Wnt inhibitor for use in head and neck squamous cell carcinoma.
Owner:IRM +1
A compound with double inhibitory effects of egfr and wnt, preparation method and application thereof
ActiveCN113444074BSignificant on-target inhibitionEasy to prepareOrganic active ingredientsOrganic chemistryWnt inhibitorDual inhibitor
The invention discloses a compound with dual inhibitory effects on EGFR and Wnt, a preparation method and application thereof, and the compound has the chemical structure shown in formula I: the research results show that the compound of formula I in the present invention has an inhibitory effect on EGFR and Wnt. All signaling pathways show significant targeted inhibition, and are expected to be used for the preparation of EGFR inhibitors, Wnt inhibitors or EGFR / Wnt dual inhibitors, especially for the preparation of treatment and / or prevention of EGFR overexpression or / or prevention. And cancer drugs mediated by over-activation of Wnt signaling pathway have medicinal prospects.
Owner:SHANGHAI UNIV OF T C M +1
Compound with EGFR and Wnt dual inhibition effects and preparation method and application thereof
ActiveCN113444074ASignificant on-target inhibitionEasy to prepareOrganic active ingredientsOrganic chemistryWnt inhibitorDual inhibitor
The invention discloses a compound with EGFR and Wnt dual inhibition effects and a preparation method and application thereof. The compound has a chemical structure as shown in a formula I. Research results show that the compound as shown in the formula I has a remarkable targeted inhibition effect on EGFR and Wnt signal channels; the compound is expected to be used for preparing an EGFR inhibitor, a Wnt inhibitor or an EGFR / Wnt dual inhibitor, is especially expected to be used for preparing a medicine for treating and / or preventing cancer mediated by EGFR overexpression or / and Wnt signaling pathway overexpression, and has a medicinal prospect.
Owner:SHANGHAI UNIV OF T C M +1
Methods for improving proliferation and stemness of limbal stem cells
ActiveUS10894945B2Increased proliferationInhibition of differentiationNervous system cellsCell culture supports/coatingWnt inhibitorBiochemistry
Provided are methods for improving the proliferation and stemness of limbal stem cells (LSCs) by adding a Wnt inhibitor to a medium for limbal explant cultures. When human limbal explants are cultured according to the methods, Wnt / β-catenin signaling is inhibited, resulting in improvement of LSC proliferation, and improvement in the stemness of LSCs, and thus the LSCs may be obtained in high yield.
Owner:THE CATHOLIC UNIV OF KOREA IND ACADEMIC COOP FOUND
Method for inducing cerebral cortex neurons
Owner:KYOTO UNIV
Platelet Production Promoter and Method of Producing Platelets Using Same
ActiveUS20190032015A1Effective massEfficient mass productionOrganic active ingredientsMammal material medical ingredientsWnt inhibitorFms-Like Tyrosine Kinase
Owner:KYOTO UNIV +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com